Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.

Schick, Markus; Habringer, Stefan; Nilsson, Jonas A; Keller, Ulrich

Schick, Markus; Habringer, Stefan; Nilsson, Jonas A; Keller, Ulrich.

Affiliation

Schick M; Internal Medicine III, School of Medicine, Technische Universität München, Munich, Germany.
Habringer S; Internal Medicine III, School of Medicine, Technische Universität München, Munich, Germany.
Nilsson JA; Department of Surgery, Sahlgrenska Cancer Center, Gothenburg University, Gothenburg, Sweden.
Keller U; Internal Medicine III, School of Medicine, Technische Universität München, Munich, Germany.

Br J Haematol ; 179(5): 724-738, 2017 12.

Article in En | MEDLINE | ID: mdl-29171017

Subject(s)

Hematologic Neoplasms/genetics; Molecular Targeted Therapy/methods; Proto-Oncogene Proteins c-myc/genetics; Biomarkers, Tumor/genetics; Biomarkers, Tumor/metabolism; Genetic Predisposition to Disease; Hematologic Neoplasms/drug therapy; Hematologic Neoplasms/metabolism; Humans; Lymphoma, B-Cell/drug therapy; Lymphoma, B-Cell/genetics; Proto-Oncogene Proteins c-myc/metabolism

Key words

MYC; leukaemia, pathogenesis; lymphoma; myeloma; synthetic lethality; targeting

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Proto-Oncogene Proteins c-myc / Hematologic Neoplasms / Molecular Targeted Therapy Type of study: Etiology_studies Limits: Humans Language: En Journal: Br J Haematol Year: 2017 Type: Article Affiliation country: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google